GlassScriptPhysician profile
Mindy S Bohrer
NPI 1902895360
$6,362.08
in general payments reported to CMS, 2019-2025
33 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $692 · 2021: $245 · 2022: $13.70 · 2023: $332 · 2024: $2,472 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200 · Long Term Medical Supply Or Device Loan: $2,196 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.95 |
| Long Term Medical Supply Or Device Loan | $2,196.36 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,772.31 | 2019-2025 | |
| Pfizer INC. | $505.77 | 2019-2025 | |
| Janssen Biotech, INC. | $477.62 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $339.73 | 2019-2025 | Enhertu, Tagrisso |
| Daiichi Sankyo INC. | $215.01 | 2020-2025 | Enhertu, Injectafer |
| Seagen INC. | $158.01 | 2019-2020 | |
| Tersera Therapeutics LLC | $152.14 | 2019-2020 | |
| Genentech USA, INC. | $132.90 | 2020-2025 | Phesgo, Itovebi, Polivy |
| Puma Biotechnology, INC. | $131.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.08 | 2024-2025 | Ninlaro, Iclusig, Fruzaqla |
| Incyte Corporation | $103.97 | 2024 | Jakafi |
| Lilly USA, LLC | $90.60 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Foundation Medicine, INC. | $80.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.71 | 2019-2025 | Lynparza, Keytruda |
| Abbvie INC. | $61.48 | 2024-2025 | |
| Celgene Corporation | $57.68 | 2020-2024 | Pomalyst |
| Astellas Pharma US INC | $56.24 | 2019 | |
| Tempus Ai, INC | $46.73 | 2024 | Xt Cdx |
| Gilead Sciences, INC. | $43.18 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $42.96 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $38.64 | 2024 | Monoferric |
| Amgen INC. | $37.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.84 | 2024 | Ojjaara |
| Helsinn Therapeutics (U.S.), INC. | $29.67 | 2019 | |
| Stemline Therapeutics INC. | $29.01 | 2025 | Orserdu |
| Octapharma USA, INC. | $26.48 | 2024 | Octagam Immune Globulin (Human) |
| Kyowa Kirin, INC. | $26.20 | 2025 | |
| Beigene USA, INC. | $16.72 | 2024 | Brukinsa |
| Pharmaand Gmbh | $13.80 | 2025 | Rubraca |
| Tolmar, INC. | $13.80 | 2025 | Eligard, Rubraca |
| Emd Serono, INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Bohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.